MX2024010977A - Composiciones que comprenden aticaprant - Google Patents
Composiciones que comprenden aticaprantInfo
- Publication number
- MX2024010977A MX2024010977A MX2024010977A MX2024010977A MX2024010977A MX 2024010977 A MX2024010977 A MX 2024010977A MX 2024010977 A MX2024010977 A MX 2024010977A MX 2024010977 A MX2024010977 A MX 2024010977A MX 2024010977 A MX2024010977 A MX 2024010977A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- aticaprant
- methods
- present disclosure
- disclosure relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317471P | 2022-03-07 | 2022-03-07 | |
| PCT/IB2023/052097 WO2023170554A1 (en) | 2022-03-07 | 2023-03-06 | Compositions comprising aticaprant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024010977A true MX2024010977A (es) | 2024-12-06 |
Family
ID=85980700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024010977A MX2024010977A (es) | 2022-03-07 | 2024-09-06 | Composiciones que comprenden aticaprant |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20230277500A1 (https=) |
| EP (1) | EP4489730B1 (https=) |
| JP (1) | JP2025508069A (https=) |
| KR (1) | KR20240152410A (https=) |
| CN (1) | CN119156202A (https=) |
| AU (1) | AU2023231767A1 (https=) |
| CA (1) | CA3254546A1 (https=) |
| CL (1) | CL2024002648A1 (https=) |
| CO (1) | CO2024012454A2 (https=) |
| ES (1) | ES3064226T3 (https=) |
| IL (1) | IL315415A (https=) |
| JO (1) | JOP20240196A1 (https=) |
| MX (1) | MX2024010977A (https=) |
| TW (1) | TW202400135A (https=) |
| UY (1) | UY40173A (https=) |
| WO (1) | WO2023170554A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| EP4489730B1 (en) | 2022-03-07 | 2026-01-21 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| WO2000069858A1 (en) | 1999-05-12 | 2000-11-23 | F. Hoffmann-La Roche Ag | Imidazodiazepine derivative |
| JP2004510789A (ja) | 2000-10-05 | 2004-04-08 | モーラー，ハンス | 選択的抗不安治療薬 |
| JP2004518654A (ja) | 2000-12-21 | 2004-06-24 | ザ マクレーン ホスピタル コーポレーション | 鬱病の治療法 |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| DE60319812T2 (de) | 2002-03-28 | 2009-04-23 | Wisys Technology Foundation, Inc., Madison | Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen |
| KR101025633B1 (ko) | 2002-09-19 | 2011-03-30 | 일라이 릴리 앤드 캄파니 | 오피오이드 수용체 안타고니스트로서의 디아릴 에테르 |
| US7396943B2 (en) | 2003-03-07 | 2008-07-08 | Eli Lilly And Company | Opioid receptor antagonists |
| CN1756746A (zh) | 2003-03-07 | 2006-04-05 | 伊莱利利公司 | 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物 |
| BRPI0417156A (pt) | 2003-12-12 | 2007-03-06 | Lilly Co Eli | composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso |
| CN1894240A (zh) | 2003-12-22 | 2007-01-10 | 伊莱利利公司 | 阿片受体拮抗剂 |
| AU2005222640A1 (en) | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| EP1727788B1 (en) | 2004-03-12 | 2010-07-28 | Eli Lilly And Company | Opioid receptor antagonists |
| EP1730140B1 (en) | 2004-03-12 | 2008-06-25 | Eli Lilly And Company | Opioid receptor antagonists |
| JP2007529523A (ja) | 2004-03-15 | 2007-10-25 | イーライ リリー アンド カンパニー | 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物 |
| CA2557794A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| US8551986B2 (en) | 2005-12-08 | 2013-10-08 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| DK2001456T3 (da) | 2006-04-04 | 2010-04-12 | Emodys Gmbh | Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser |
| US20100222345A1 (en) | 2006-08-09 | 2010-09-02 | Caroline Jean Diaz | Novel compounds as antagonists or inverse agonists for opioid receptors |
| WO2008021849A2 (en) | 2006-08-09 | 2008-02-21 | Smithkline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
| CN101511808A (zh) | 2006-09-08 | 2009-08-19 | 辉瑞产品公司 | 二芳基醚衍生物及其用途 |
| WO2009094260A1 (en) | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| AU2010316683B2 (en) * | 2009-11-09 | 2015-10-08 | Wyeth Llc | Tablet formulations of neratinib maleate |
| BR112013002846A2 (pt) | 2010-08-05 | 2016-06-07 | Conrig Pharma Aps | derivados de tandospirona deuterada como agonista do receptor de 5-ht1a |
| EP2773352B1 (en) | 2011-12-09 | 2017-06-28 | Research Triangle Institute | 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists |
| MX368870B (es) | 2013-12-20 | 2019-10-21 | H Lundbeck As | Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas. |
| US10377698B2 (en) | 2015-03-30 | 2019-08-13 | University Of Innsbruck | Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production |
| US10709685B2 (en) | 2015-05-28 | 2020-07-14 | Georgetown University | Use of methadone metabolites for treatment of anxiety and depression |
| SI3881833T1 (sl) * | 2015-06-30 | 2024-03-29 | Genentech, Inc., | Tablete s takojšnjim sproščanjem, ki vsebujejo zdravilo in postopek za oblikovanje tablet |
| WO2017218518A1 (en) | 2016-06-13 | 2017-12-21 | Board Of Regents Of The University Of Texas System | Pharmaceutical compositions and methods for treatment of pain |
| EP3490542A4 (en) | 2016-07-26 | 2020-07-08 | Flagship Pioneering Innovations V, Inc. | NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE |
| JP7048572B6 (ja) | 2016-09-16 | 2023-12-20 | リサーチ トライアングル インスティテュート | テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| ES2926533T3 (es) | 2017-03-17 | 2022-10-26 | Scripps Research Inst | Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos |
| PH12018000077B1 (en) * | 2017-07-05 | 2021-07-09 | Frimline Private Ltd | A pharmaceutical composition for neuropathic pain |
| US20190255036A1 (en) | 2018-02-16 | 2019-08-22 | Alexander Kariman | Compound and method for reducing neuropathic pain and depression |
| WO2019183556A1 (en) | 2018-03-23 | 2019-09-26 | University Of Kansas | Cyclic tetrapeptide analogs |
| US11491144B2 (en) | 2018-03-30 | 2022-11-08 | The Florida State University Research Foundation, Incorporated | Methods of treating fragile X mental retardation syndrome |
| JP2022505676A (ja) | 2018-10-23 | 2022-01-14 | ブラックソーン セラピューティクス インコーポレイテッド | 患者のスクリーニング、診断、及び層別化のためのシステム及び方法 |
| US20200171025A1 (en) * | 2018-11-29 | 2020-06-04 | Srinivasa Rao Parella | Pharmaceutical composition comprising brexpiprazole and process for preparation thereof |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| AU2022268720A1 (en) * | 2021-05-04 | 2023-12-21 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170547A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Pure forms of crystalline aticaprant |
| CN119156211A (zh) | 2022-03-07 | 2024-12-17 | 杨森制药公司 | 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰 |
| EP4489730B1 (en) | 2022-03-07 | 2026-01-21 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
-
2023
- 2023-03-06 EP EP23716356.3A patent/EP4489730B1/en active Active
- 2023-03-06 UY UY0001040173A patent/UY40173A/es unknown
- 2023-03-06 ES ES23716356T patent/ES3064226T3/es active Active
- 2023-03-06 CN CN202380038806.7A patent/CN119156202A/zh active Pending
- 2023-03-06 TW TW112108149A patent/TW202400135A/zh unknown
- 2023-03-06 KR KR1020247033299A patent/KR20240152410A/ko active Pending
- 2023-03-06 JP JP2024553421A patent/JP2025508069A/ja active Pending
- 2023-03-06 WO PCT/IB2023/052097 patent/WO2023170554A1/en not_active Ceased
- 2023-03-06 AU AU2023231767A patent/AU2023231767A1/en active Pending
- 2023-03-06 IL IL315415A patent/IL315415A/en unknown
- 2023-03-06 CA CA3254546A patent/CA3254546A1/en active Pending
- 2023-03-06 US US18/179,093 patent/US20230277500A1/en not_active Abandoned
-
2024
- 2024-03-27 US US18/618,520 patent/US12201610B2/en active Active
- 2024-09-04 CL CL2024002648A patent/CL2024002648A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0196A patent/JOP20240196A1/ar unknown
- 2024-09-06 MX MX2024010977A patent/MX2024010977A/es unknown
- 2024-09-13 CO CONC2024/0012454A patent/CO2024012454A2/es unknown
-
2025
- 2025-01-16 US US19/023,669 patent/US20250228819A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240152410A (ko) | 2024-10-21 |
| IL315415A (en) | 2024-11-01 |
| US12201610B2 (en) | 2025-01-21 |
| US20240269110A1 (en) | 2024-08-15 |
| CO2024012454A2 (es) | 2024-09-30 |
| ES3064226T3 (en) | 2026-04-23 |
| UY40173A (es) | 2023-09-29 |
| AU2023231767A1 (en) | 2024-10-24 |
| CL2024002648A1 (es) | 2025-01-24 |
| TW202400135A (zh) | 2024-01-01 |
| US20230277500A1 (en) | 2023-09-07 |
| CN119156202A (zh) | 2024-12-17 |
| CA3254546A1 (en) | 2023-09-14 |
| EP4489730B1 (en) | 2026-01-21 |
| WO2023170554A1 (en) | 2023-09-14 |
| JP2025508069A (ja) | 2025-03-21 |
| JOP20240196A1 (ar) | 2024-09-05 |
| EP4489730C0 (en) | 2026-01-21 |
| US20250228819A1 (en) | 2025-07-17 |
| EP4489730A1 (en) | 2025-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010977A (es) | Composiciones que comprenden aticaprant | |
| CO2019009258A2 (es) | Administración rápida y controlada de composiciones con efectos séquito restaurados | |
| CO2022003782A2 (es) | Inhibidores de kras g12d | |
| CO2019006291A2 (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
| AR106768A1 (es) | Composiciones que comprenden cepas bacterianas | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| MX2021001716A (es) | Composiciones novedosas, su uso y metodos para su formacion. | |
| MX366925B (es) | Inhibidores de ibat para el tratamiento de enfermedades hepaticas. | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| MX2022002946A (es) | Inhibidores de cdk y su uso como productos farmaceuticos. | |
| CO2019011265A2 (es) | Moduladores de la expresión de pcsk9 | |
| MX2022001449A (es) | Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos. | |
| EA201891440A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| CL2019002340A1 (es) | Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1. | |
| CO2022005952A2 (es) | Extracto de algas concentrado | |
| AR112587A1 (es) | Psicosa-6-fosfato fosfatasa, composición para producir d-psicosa que comprende la enzima y métodos para producir d-psicosa utilizando la enzima | |
| MX2018007871A (es) | Composiciones para el cuidado personal. | |
| MX2016015961A (es) | Composiciones farmacéuticas que comprenden ácido dihomo-gamma-linolénico (dgla) y uso de las mismas. | |
| EA201591755A1 (ru) | Композиции для лечения ксеростомии и для лечения зубов | |
| CO6300935A2 (es) | Formulaciones orales e inyectables de compuestos de tetraciclina | |
| MX2019004579A (es) | Composiciones para el cuidado bucal y metodos de uso. | |
| MX2019008460A (es) | Metodos para tratar esclerosis multiple usando celulas t autologas. | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| CL2019003801A1 (es) | Nuevas formulaciones orales de belinostato. |